{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:32:13Z","timestamp":1772044333908,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T00:00:00Z","timestamp":1474243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T00:00:00Z","timestamp":1474243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) is the most common form of dementia. Cellular AD models derived from human pluripotent stem cells are promising tools in AD research. We recently developed human embryonic stem cell-derived AD models which overexpress mutant Presenilin1 genes, and which exhibit AD phenotypes, including synaptic dysfunction. In this study, we found that our AD models showed reduced levels of RAB3A and SV2B proteins in the pre-synapses, which is a possible cause of electrophysiological abnormalities. Through the screening of chemical compounds using our AD models, we have identified A\u03b2 peptide inhibitors which decrease the concentration of A\u03b2 in culture supernatant. Among these, BMS-708163 and Nilotinib were found to improve the expression levels of RAB3A and SV2B proteins and to recover the electrophysiological function in our AD models. These results suggest that the AD models we developed are promising materials for the discovery of AD drugs that target the expression of pre-synaptic proteins and synaptic function.<\/jats:p>","DOI":"10.1038\/srep33427","type":"journal-article","created":{"date-parts":[[2016,9,19]],"date-time":"2016-09-19T10:06:00Z","timestamp":1474279560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer\u2019s disease models"],"prefix":"10.1038","volume":"6","author":[{"given":"Hisae","family":"Nishioka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norie","family":"Tooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehisa","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Nakatsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Aiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,19]]},"reference":[{"key":"BFsrep33427_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nature Rev Mol Cell Biol 8, 101\u2013112 (2007).","journal-title":"Nature Rev Mol Cell Biol"},{"key":"BFsrep33427_CR2","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.neuropharm.2010.07.012","volume":"59","author":"GA Krafft","year":"2010","unstructured":"Krafft, G. A. & Klein, W. L. ADDLs and the signaling web that leads to Alzheimer\u2019s disease. Neuropharmacology 59, 230\u2013242 (2010).","journal-title":"Neuropharmacology"},{"key":"BFsrep33427_CR3","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1074\/jbc.271.8.4077","volume":"271","author":"Y-M Kuo","year":"1996","unstructured":"Kuo, Y.-M. et al. Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains. J Biol Chem 271, 4077\u20134081 (1996).","journal-title":"J Biol Chem"},{"key":"BFsrep33427_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar, G. M. et al. Amyloid-\u03b2 protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med 14, 837\u2013842 (2008).","journal-title":"Nat Med"},{"key":"BFsrep33427_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/0891988710383571","volume":"23","author":"LM Bekris","year":"2010","unstructured":"Bekris, L. M. et al. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23, 213\u2013227 (2010).","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"BFsrep33427_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2741\/E605","volume":"5","author":"I Piaceri","year":"2013","unstructured":"Piaceri, I. et al. Genetics of familial and sporadic Alzheimer\u2019s disease. Front Biosci 5, 167\u2013177 (2013).","journal-title":"Front Biosci"},{"key":"BFsrep33427_CR7","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/0092-8674(93)90312-E","volume":"75","author":"C Haass","year":"1993","unstructured":"Haass, C. & Selkoe, D. J. Cellular processing of \u03b2-amyloid precursor protein and the genesis of amyloid \u03b2-peptide. Cell 75, 1039\u20131042 (1993).","journal-title":"Cell"},{"key":"BFsrep33427_CR8","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1186\/1750-1326-7-52","volume":"7","author":"L Chami","year":"2012","unstructured":"Chami, L. & Checler, F. BACE1 is at the crossroad of a toxic vicious cycle involving cellular stress and beta-amyloid production in Alzheimer\u2019s disease. Mol Neurodegen 7, 1750\u20131326 (2012).","journal-title":"Mol Neurodegen"},{"key":"BFsrep33427_CR9","doi-asserted-by":"publisher","first-page":"29615","DOI":"10.1074\/jbc.R800019200","volume":"283","author":"G Thinakaran","year":"2008","unstructured":"Thinakaran, G. & Koo, E. H. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 283, 29615\u201329619 (2008).","journal-title":"J Biol Chem"},{"key":"BFsrep33427_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0896-6273(00)80230-5","volume":"17","author":"DR Borchelt","year":"1996","unstructured":"Borchelt, D. R. et al. Familial Alzheimer\u2019s Disease\u2013Linked Presenilin 1 Variants Elevate A\u03b21\u201342\/1\u201340 Ratio In Vitro and In Vivo. Neuron 17, 1005\u20131013 (1996).","journal-title":"Neuron"},{"key":"BFsrep33427_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/383710a0","volume":"383","author":"K Duff","year":"1996","unstructured":"Duff, K. et al. Increased amyloid-\u03b242(43) in brains of mice expressing mutant presenilin 1. Nature 383, 710\u2013713 (1996).","journal-title":"Nature"},{"key":"BFsrep33427_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/sj.emboj.7600061","volume":"23","author":"C Haass","year":"2004","unstructured":"Haass, C. Take five\u2013BACE and the gamma-secretase quartet conduct Alzheimer\u2019s amyloid beta-peptide generation. Embo J 23, 483\u2013488 (2004).","journal-title":"Embo J"},{"key":"BFsrep33427_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.mam.2015.06.007","volume":"43\u201344","author":"AA Sproul","year":"2015","unstructured":"Sproul, A. A. Being human: The role of pluripotent stem cells in regenerative medicine and humanizing Alzheimer\u2019s disease models. Mol Aspects Med 43\u201344, 54\u201365 (2015).","journal-title":"Mol Aspects Med"},{"key":"BFsrep33427_CR14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/clpt.2011.38","volume":"89","author":"H Inoue","year":"2011","unstructured":"Inoue, H. & Yamanaka, S. The use of induced pluripotent stem cells in drug development. Clin Pharmacol Ther 89, 655\u2013661 (2011).","journal-title":"Clin Pharmacol Ther"},{"key":"BFsrep33427_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1042\/BST0381051","volume":"38","author":"D Laustriat","year":"2010","unstructured":"Laustriat, D. et al. Human pluripotent stem cells in drug discovery and predictive toxicology. Biochem Soc Trans 38, 1051\u20131057 (2010).","journal-title":"Biochem Soc Trans"},{"key":"BFsrep33427_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1750-1326-9-3","volume":"9","author":"L Duan","year":"2014","unstructured":"Duan, L. et al. Stem cell derived basal forebrain cholinergic neurons from Alzheimer\u2019s disease patients are more susceptible to cell death. Mol Neurodegen 9, 3 (2014).","journal-title":"Mol Neurodegen"},{"key":"BFsrep33427_CR17","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/nature10821","volume":"482","author":"MA Israel","year":"2012","unstructured":"Israel, M. A. et al. Probing sporadic and familial Alzheimer\/\u2018s disease using induced pluripotent stem cells. Nature 482, 216\u2013220 (2012).","journal-title":"Nature"},{"key":"BFsrep33427_CR18","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1001\/jamaneurol.2014.2482","volume":"71","author":"Q Liu","year":"2014","unstructured":"Liu, Q. et al. EFfect of potent \u03b3-secretase modulator in human neurons derived from multiple presenilin 1\u2013induced pluripotent stem cell mutant carriers. JAMA Neurology 71, 1481\u20131489 (2014).","journal-title":"JAMA Neurology"},{"key":"BFsrep33427_CR19","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.1093\/hmg\/ddu064","volume":"23","author":"CR Muratore","year":"2014","unstructured":"Muratore, C. R. et al. The familial Alzheimer\u2019s disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons. Hum Mol Gen 23, 3523\u20133536 (2014).","journal-title":"Hum Mol Gen"},{"key":"BFsrep33427_CR20","doi-asserted-by":"publisher","first-page":"e84547","DOI":"10.1371\/journal.pone.0084547","volume":"9","author":"AA Sproul","year":"2014","unstructured":"Sproul, A. A. et al. Characterization and Molecular Profiling of PSEN1 Familial Alzheimer\u2019s Disease iPSC-Derived Neural Progenitors. PloS one 9, e84547 (2014).","journal-title":"PloS one"},{"key":"BFsrep33427_CR21","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.celrep.2013.10.018","volume":"5","author":"G Woodruff","year":"2013","unstructured":"Woodruff, G. et al. The Presenilin-1 \u0394E9 Mutation Results in Reduced \u03b3-Secretase Activity, but Not Total Loss of PS1 Function, in Isogenic Human Stem Cells. Cell Rep 5, 974\u2013985 (2013).","journal-title":"Cell Rep"},{"key":"BFsrep33427_CR22","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.1093\/hmg\/ddr394","volume":"20","author":"T Yagi","year":"2011","unstructured":"Yagi, T. et al. Modeling familial Alzheimer\u2019s disease with induced pluripotent stem cells. Hum Mol Gen 20, 4530\u20134539 (2011).","journal-title":"Hum Mol Gen"},{"key":"BFsrep33427_CR23","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1074\/jbc.R113.488247","volume":"289","author":"M Li","year":"2014","unstructured":"Li, M. et al. A Cut above the Rest: Targeted Genome Editing Technologies in Human Pluripotent Stem Cells. J Biol Chem 289, 4594\u20134599 (2014).","journal-title":"J Biol Chem"},{"key":"BFsrep33427_CR24","doi-asserted-by":"crossref","unstructured":"Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. Science 346 (2014).","DOI":"10.1126\/science.1258096"},{"key":"BFsrep33427_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/nar\/gkp1234","volume":"38","author":"K Sakurai","year":"2010","unstructured":"Sakurai, K. et al. Efficient integration of transgenes into a defined locus in human embryonic stem cells. Nucleic Acids Res 38, 13 (2010).","journal-title":"Nucleic Acids Res"},{"key":"BFsrep33427_CR26","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.bbrc.2015.12.025","volume":"469","author":"M Honda","year":"2016","unstructured":"Honda, M. et al. The modeling of Alzheimer\u2019s disease by the overexpression of mutant Presenilin 1 in human embryonic stem cells. Biochem Biophys Res Commun 469, 587\u2013592 (2016).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep33427_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1124\/jpet.106.110700","volume":"319","author":"TA Lanz","year":"2006","unstructured":"Lanz, T. A. et al. Concentration-Dependent Modulation of Amyloid-\u03b2 in Vivo and in Vitro Using the \u03b3-Secretase Inhibitor, LY-450139. J Pharmacol Exp Ther 319, 924\u2013933 (2006).","journal-title":"J Pharmacol Exp Ther"},{"key":"BFsrep33427_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1021\/ml1000239","volume":"1","author":"KW Gillman","year":"2010","unstructured":"Gillman, K. W. et al. Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable \u03b3-Secretase Inhibitor. ACS Med Chem Lett 1, 120\u2013124 (2010).","journal-title":"ACS Med Chem Lett"},{"key":"BFsrep33427_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1124\/jpet.102.048280","volume":"305","author":"TA Lanz","year":"2003","unstructured":"Lanz, T. A. et al. The \u03b3-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces A\u03b2 Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice. J Pharmacol Exp Ther 305, 864\u2013871 (2003).","journal-title":"J Pharmacol Exp Ther"},{"key":"BFsrep33427_CR30","first-page":"531","volume":"21","author":"H Kurinami","year":"2008","unstructured":"Kurinami, H. et al. Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model. Int J Mol Med 21, 531\u2013537 (2008).","journal-title":"Int J Mol Med"},{"key":"BFsrep33427_CR31","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s00109-013-1112-3","volume":"92","author":"I Lonskaya","year":"2014","unstructured":"Lonskaya, I. et al. Nilotinib-induced autophagic changes increase endogenous parkin level and ubiquitination, leading to amyloid clearance. J Mol Med (Berl) 92, 373\u2013386 (2014).","journal-title":"J Mol Med (Berl)"},{"key":"BFsrep33427_CR32","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.neurobiolaging.2003.04.005","volume":"24","author":"WG Honer","year":"2003","unstructured":"Honer, W. G. Pathology of presynaptic proteins in Alzheimer\u2019s disease: more than simple loss of terminals. Neurobiol Aging 24, 1047\u20131062 (2003).","journal-title":"Neurobiol Aging"},{"key":"BFsrep33427_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/WNL.56.1.127","volume":"56","author":"E Masliah","year":"2001","unstructured":"Masliah, E. et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer\u2019s disease. Neurology 56, 127\u2013129 (2001).","journal-title":"Neurology"},{"key":"BFsrep33427_CR34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/toxsci\/kfh254","volume":"82","author":"J Milano","year":"2004","unstructured":"Milano, J. et al. Modulation of Notch Processing by \u03b3-Secretase Inhibitors Causes Intestinal Goblet Cell Metaplasia and Induction of Genes Known to Specify Gut Secretory Lineage Differentiation. Toxicol Sci 82, 341\u2013358 (2004).","journal-title":"Toxicol Sci"},{"key":"BFsrep33427_CR35","doi-asserted-by":"publisher","first-page":"6743","DOI":"10.1523\/JNEUROSCI.1381-10.2010","volume":"30","author":"JJ Cook","year":"2010","unstructured":"Cook, J. J. et al. Acute \u03b3-Secretase Inhibition of Nonhuman Primate CNS Shifts Amyloid Precursor Protein (APP) Metabolism from Amyloid-\u03b2 Production to Alternative APP Fragments without Amyloid-\u03b2 Rebound. J Neurosci 30, 6743\u20136750 (2010).","journal-title":"J Neurosci"},{"key":"BFsrep33427_CR36","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/jpet.103.060715","volume":"309","author":"TA Lanz","year":"2004","unstructured":"Lanz, T. A. et al. Studies of A\u03b2 Pharmacodynamics in the Brain, Cerebrospinal Fluid, and Plasma in Young (Plaque-Free) Tg2576 Mice Using the \u03b3-Secretase Inhibitor N2-[(2S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). J Pharmacol Exp Ther 309, 49\u201355 (2004).","journal-title":"J Pharmacol Exp Ther"},{"key":"BFsrep33427_CR37","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/cdd.2011.140","volume":"19","author":"JY Kim","year":"2012","unstructured":"Kim, J. Y. et al. Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-\u03b2 plaques. Cell Death Differ 19, 680\u2013691 (2012).","journal-title":"Cell Death Differ"},{"key":"BFsrep33427_CR38","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","volume":"30","author":"DL DeRemer","year":"2008","unstructured":"DeRemer, D. L. et al. Nilotinib: A second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 30, 1956\u20131975 (2008).","journal-title":"Clin Ther"},{"key":"BFsrep33427_CR39","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/j.chembiol.2011.11.001","volume":"18","author":"T Skorski","year":"2011","unstructured":"Skorski, T. BCR-ABL1 Kinase: Hunting an Elusive Target with New Weapons. Chem Biol 18, 1352\u20131353 (2011).","journal-title":"Chem Biol"},{"key":"BFsrep33427_CR40","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/emmm.201302771","volume":"5","author":"I Lonskaya","year":"2013","unstructured":"Lonskaya, I. et al. Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance. EMBO Mol Med 5, 1247\u20131262 (2013).","journal-title":"EMBO Mol Med"},{"key":"BFsrep33427_CR41","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.2217\/pgs.12.103","volume":"13","author":"S Soverini","year":"2012","unstructured":"Soverini, S. et al. Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis. Pharmacogenomics 13, 1271\u20131284 (2012).","journal-title":"Pharmacogenomics"},{"key":"BFsrep33427_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/jcpt.12112","volume":"39","author":"JA Mikulca","year":"2014","unstructured":"Mikulca, J. A. et al. Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches. J Clin Pharm Ther 39, 25\u201337 (2014).","journal-title":"J Clin Pharm Ther"},{"key":"BFsrep33427_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","volume":"275","author":"LS Schneider","year":"2014","unstructured":"Schneider, L. S. et al. Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014. J Intern Med 275, 251\u2013283 (2014).","journal-title":"J Intern Med"},{"key":"BFsrep33427_CR44","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/7854_2011_153","volume":"10","author":"J Corey-Bloom","year":"2012","unstructured":"Corey-Bloom, J. Treatment trials in aging and mild cognitive impairment. Curr Top Behav Neurosci 10, 347\u2013356 (2012).","journal-title":"Curr Top Behav Neurosci"},{"key":"BFsrep33427_CR45","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1126\/science.6338589","volume":"219","author":"J Coyle","year":"1983","unstructured":"Coyle, J. et al. Alzheimer\u2019s disease: a disorder of cortical cholinergic innervation. Science 219, 1184\u20131190 (1983).","journal-title":"Science"},{"key":"BFsrep33427_CR46","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1111\/j.1582-4934.2009.00916.x","volume":"14","author":"M Nilbratt","year":"2010","unstructured":"Nilbratt, M. et al. Neurotrophic factors promote cholinergic differentiation in human embryonic stem cell-derived neurons. J Cell Mol Med 14, 1476\u20131484 (2010).","journal-title":"J Cell Mol Med"},{"key":"BFsrep33427_CR47","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/stem.626","volume":"29","author":"CJ Bissonnette","year":"2011","unstructured":"Bissonnette, C. J. et al. The Controlled Generation of Functional Basal Forebrain Cholinergic Neurons from Human Embryonic Stem Cells. Stem Cells 29, 802\u2013811 (2011).","journal-title":"Stem Cells"},{"key":"BFsrep33427_CR48","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.bbrc.2006.04.135","volume":"345","author":"H Suemori","year":"2006","unstructured":"Suemori, H. et al. Efficient establishment of human embryonic stem cell lines and long-term maintenance with stable karyotype by enzymatic bulk passage. Biochem Biophys Res Commun 345, 926\u2013932 (2006).","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep33427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep33427","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep33427.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T06:55:31Z","timestamp":1672901731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep33427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,19]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,16]]}},"alternative-id":["BFsrep33427"],"URL":"https:\/\/doi.org\/10.1038\/srep33427","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,19]]},"assertion":[{"value":"8 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.N. is a shareholder of ReproCELL. H.N., T.I., N.T., and K.A. declare no potential conflicts of interest in association with this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33427"}}